0001104659-22-023774.txt : 20220215
0001104659-22-023774.hdr.sgml : 20220215
20220215160237
ACCESSION NUMBER: 0001104659-22-023774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210716
FILED AS OF DATE: 20220215
DATE AS OF CHANGE: 20220215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meek David D.
CENTRAL INDEX KEY: 0001555337
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 22639142
MAIL ADDRESS:
STREET 1: 3000 KENT AVENUE; SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001724344
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824592913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 810-0120
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Entasis Therapeutics Ltd
DATE OF NAME CHANGE: 20171204
4
1
tm226724-5_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-07-16
0
0001724344
Entasis Therapeutics Holdings Inc.
ETTX
0001555337
Meek David D.
C/O ENTASIS THERAPEUTICS HOLDINGS INC.,
35 GATEHOUSE DRIVE
WALTHAM
MA
02451
1
0
0
0
Stock Option (Right to Buy)
6.12
2021-07-16
4
D
0
15000
D
2029-06-18
Common Stock
15000
0
D
Stock Option (Right to Buy)
2.44
2021-07-16
4
A
0
11538
A
2031-07-15
Common Stock
11538
11538
D
Stock Option (Right to Buy)
6.12
2021-07-16
4
D
0
7500
D
2029-06-18
Common Stock
7500
0
D
Stock Option (Right to Buy)
2.44
2021-07-16
4
A
0
5769
A
2031-07-15
Common Stock
5769
5769
D
The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date.
On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share.
The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date.
On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share.
The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
Elizabeth M. Keiley as Attorney-in-Fact for David Meek
2022-02-14